Showing 1941-1950 of 5771 results for "".
- Envision Announces Call for Applications for Next Class of Research Fellowshttps://modernod.com/news/envision-announces-call-for-applications-for-next-class-of-research-fellows/2478919/Envision announced that it has created two new research fellowship opportunities to be carried out through the Gigi & Carl Allen Envision Research Institute (ERI) in Wichita. Selected projects will start between April through the end of Summer 2021. Established in 2015, the Envision Re
- Glaukos Announces Positive Phase 3 Trial Results for iLink Epi-On Investigational Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-trial-results-for-ilink-epi-on-investigational-therapy/2478917/Glaukos announced that U.S. phase 3 pivotal trial results for its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, known as Epi-on, met the study’s primary efficacy endpoint, demonstrating a statistically significant improvement in maximum corneal curvature (K
- FCI Ophthalmics Announces Availability of LacriJet for Monocanalicular Nasolacrimal Intubationhttps://modernod.com/news/fci-ophthalmics-announces-availability-of-lacrijet-for-monocanalicular-nasolacrimal-intubation/2478907/FCI Ophthalmics announced the launch of the LacriJet in the United States. It is the first, self-retaining monocanalicular nasolacrimal intubation preloaded on a single use injector, according to FCI Ophthalmics. LacriJet consists of a single use injector handpiece into which a silicone tu
- Topcon Announces US Launch of the Harmony Glaucoma Modulehttps://modernod.com/news/topcon-announces-us-launch-of-the-harmony-glaucoma-module/2478906/Topcon Healthcare announced it has launched its new Glaucoma Module feature for the Harmony Clinical Data Management Solution. The new Glaucoma Module provides eye care professionals easy access to the information needed to diagnose and manage glaucoma on a single screen. The Hood Dashboar
- Nicox Announces the Publication of Preclinical Efficacy Results on a New Class of Non-PGA NO-Donating IOP-Lowering Compoundshttps://modernod.com/news/nicox-announces-the-publication-of-preclinical-efficacy-results-on-a-new-class-of-non-pga-no-donating-iop-lowering-compounds/2478896/Nicox SA announced the publication of preclinical IOP-lowering results on a new class of non-prostaglandin analog (PGA), nitric oxide (NO)-donating compounds, in the Journal of Ocular Pharmacology and Therapeutics.1 The NO-mediated IOP-lowering effect in this new class of comp
- Alcon Announces Broad Retail Availability of Pataday Once Daily Relief Extra Strength in the UShttps://modernod.com/news/alcon-announces-broad-retail-availability-of-pataday-once-daily-relief-extra-strength-in-the-u-s/2478886/Alcon announced that Pataday Once Daily Relief Extra Strength is now available in-store and online at U.S. retailers following its 2020 approval by the FDA for sale over the counter (OTC). As Alcon’s third Rx-to-OTC switch in the past 12 months, Pataday Once Daily Relief Extra Strength (o
- Kodiak Sciences Announces 1-Year Data from Ongoing Phase 1b Study of KSI-301 in Patients with Retinal Vascular Diseaseshttps://modernod.com/news/kodiak-sciences-announces-1-year-data-from-ongoing-phase-1b-study-of-ksi-301-in-patients-with-retinal-vascular-diseases/2478877/Kodiak Sciences announced promising 1-year durability, efficacy and safety data from the ongoing phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-naïve wet age-related macular d
- LumiThera Announces Positive Interim Data in Visual and ERG Clinical Outcomes in the ELECTROLIGHT Pilot Study in Dry AMD Patientshttps://modernod.com/news/lumithera-announces-positive-interim-data-in-visual-and-erg-clinical-outcomes-in-the-electrolight-pilot-study-in-dry-amd-patients/2478872/LumiThera announced the interim data from the ELECTROLIGHT pilot study in dry AMD patients. A total of 23 eyes from 15 subjects with intermediate dry AMD were enrolled into the prospective clinical study and treated with PBM using the Valeda Light Delivery System (3 times per week for 3 we
- Clearside Biomedical Announces CLS-AX Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Programhttps://modernod.com/news/clearside-biomedical-announces-cls-ax-presentation-delivered-at-angiogenesis-exudation-and-degeneration-2021-program/2478874/Clearside Biomedical announced that David M. Brown, MD, delivered a presentation entitled, “Axitinib: A Novel TKI Delivered by Suprachoroidal Injection for AMD” at the virtual Angiogenesis, Exudation, and Degeneration 2021 program hosted by the University of Miami Health System Ba
- Kala Pharmaceuticals Announces Eysuvis Now Covered by Express Scriptshttps://modernod.com/news/kala-pharmaceuticals-announces-eysuvis-now-covered-by-express-scripts/2478871/Kala Pharmaceuticals announced that pharmacy benefit manager Express Scripts has added Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% to its National Preferred, Basic and High Performance Formularies, effective February 5, 2021. Eysuvis is the first and only prescription therapy appr